Zemplar

Paricalcitol is a vitamin D analog used to manage secondary hyperparathyroidism in chronic kidney disease. This intravenous form supports balanced calcium levels when oral options are unsuitable. A key option for patients requiring dialysis or with limited oral absorption. Short, neutral overview for quick reference.

Paricalcitol is primarily used to treat secondary hyperparathyroidism in adults with chronic kidney disease who are on dialysis. It helps regulate calcium and phosphorus levels by acting on vitamin D receptors. This medication is prescribed when the body’s natural vitamin D production is insufficient due to kidney dysfunction. It is not intended for use in conditions unrelated to secondary hyperparathyroidism.

Paricalcitol works by mimicking the effects of vitamin D, which helps control parathyroid hormone levels. Patients may notice improved calcium balance and reduced symptoms related to high parathyroid hormone. The effects are gradual and intended to support long-term kidney health. Individual responses can vary based on medical condition and treatment plan.

Paricalcitol should be administered under medical supervision, typically in a clinical setting. Regular blood tests are recommended to monitor calcium, phosphorus, and parathyroid hormone levels during treatment. Patients with a history of high calcium levels or certain bone disorders should use this medication with caution. Always inform your healthcare provider about current medications and health conditions before starting paricalcitol.

Paricalcitol may interact with medications that affect calcium levels, such as thiazide diuretics or calcium supplements. Strong CYP3A inhibitors, like certain antifungals or antibiotics, can increase paricalcitol levels in the blood. Avoid taking additional vitamin D or its analogs without consulting a healthcare provider. Alcohol and grapefruit products may also influence how paricalcitol works in the body.